Form 4: Syndax Pharmaceuticals Executive Acquires and Disposes of Shares
SEC Form 4
Nicholas A.J. Botwood, Head of R&D and CMO of Syndax Pharmaceuticals, reports a transaction involving the acquisition and disposition of common stock on May 16, 2025.
Summary
- On May 16, 2025, Nicholas A.J. Botwood, Head of R&D and CMO at Syndax Pharmaceuticals Inc. (SNDX), engaged in a transaction involving the company's common stock.
- Botwood acquired 11,765 shares of common stock at a price of $8.995 per share.
- Following the reported transaction, Botwood beneficially owns 35,165 shares.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider trading activity. The sentiment is neutral as it simply reports transactions without indicating a positive or negative outlook.
Industry Context
Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their trading activities and potential alignment with company performance.
Stakeholder Impact
- The transaction may provide stakeholders with insights into management's perspective on the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of stock transaction (acquisition and disposition). |
| 05/19/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Syndax Pharmaceuticals, SNDX, Nicholas A.J. Botwood, Form 4, Beneficial Ownership, Stock Transaction, Head of R&D, CMO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.